The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat

John Panozzo; Ender Akan; T. Daniel Griffiths; Gayle E. Woloschak

doi:10.1016/0304-3835(96)04285-1

The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat

John Panozzo, Ender Akan, T. Daniel Griffiths, Gayle E. Woloschak^*

^*Corresponding author for this work

Radiation Oncology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Previous work by many groups has documented induction of the human immunodeficiency virus (HIV) long terminal repeat (LTR) following exposure of cells to ultraviolet light and other DNA damaging agents. Our experiments set out to determine the relative activation or repression of the HIV-LTR in response to two classes of chemotherapeutic agents: Doxorubicin is a DNA damage-inducing agent, and 5-fluorouracil has an antimetabolic mode of action. Using HeLa cells stably transfected with a construct in which HIV-LTR drives expression of the chloramphenicol acetyl transferase reporter gene, we demonstrated an up to ten-fold induction following doxorubicin treatment at 24 h post-treatment. This induction was repressed by treatment with salicylic acid, suggesting a role for prostaglandin/cyclo-oxygenase pathways and/or NF-κB in the inductive response. Induction by 5-fluorouracil, in contrast, was more modest (two-fold at most) though it was consistently elevated over controls.

Original language	English (US)
Pages (from-to)	217-223
Number of pages	7
Journal	Cancer Letters
Volume	105
Issue number	2
DOIs	https://doi.org/10.1016/0304-3835(96)04285-1
State	Published - Aug 2 1996

Funding

for excellent secretarial assistance and Drs. Jeff Schwartz, Meyrick Peak and David Grdina for critical review of the manuscript. This work is supported by the U.S. Department of Energy, Office of Health and Environmental Research, under Contract No. W-31-109-ENG-38.

Keywords

5-Fluorouracil
Chemotherapeutic agents
Doxorubicin/adriamycin
Human immunodeficiency virus (HIV) gene expression
Long terminal repeat of HIV

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0304-3835(96)04285-1

Cite this

@article{dc1f6187597d4175b293190432134e01,

title = "The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat",

abstract = "Previous work by many groups has documented induction of the human immunodeficiency virus (HIV) long terminal repeat (LTR) following exposure of cells to ultraviolet light and other DNA damaging agents. Our experiments set out to determine the relative activation or repression of the HIV-LTR in response to two classes of chemotherapeutic agents: Doxorubicin is a DNA damage-inducing agent, and 5-fluorouracil has an antimetabolic mode of action. Using HeLa cells stably transfected with a construct in which HIV-LTR drives expression of the chloramphenicol acetyl transferase reporter gene, we demonstrated an up to ten-fold induction following doxorubicin treatment at 24 h post-treatment. This induction was repressed by treatment with salicylic acid, suggesting a role for prostaglandin/cyclo-oxygenase pathways and/or NF-κB in the inductive response. Induction by 5-fluorouracil, in contrast, was more modest (two-fold at most) though it was consistently elevated over controls.",

keywords = "5-Fluorouracil, Chemotherapeutic agents, Doxorubicin/adriamycin, Human immunodeficiency virus (HIV) gene expression, Long terminal repeat of HIV",

author = "John Panozzo and Ender Akan and Griffiths, \{T. Daniel\} and Woloschak, \{Gayle E.\}",

note = "Funding Information: for excellent secretarial assistance and Drs. Jeff Schwartz, Meyrick Peak and David Grdina for critical review of the manuscript. This work is supported by the U.S. Department of Energy, Office of Health and Environmental Research, under Contract No. W-31-109-ENG-38.",

year = "1996",

month = aug,

day = "2",

doi = "10.1016/0304-3835(96)04285-1",

language = "English (US)",

volume = "105",

pages = "217--223",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat

AU - Panozzo, John

AU - Akan, Ender

AU - Griffiths, T. Daniel

AU - Woloschak, Gayle E.

N1 - Funding Information: for excellent secretarial assistance and Drs. Jeff Schwartz, Meyrick Peak and David Grdina for critical review of the manuscript. This work is supported by the U.S. Department of Energy, Office of Health and Environmental Research, under Contract No. W-31-109-ENG-38.

PY - 1996/8/2

Y1 - 1996/8/2

N2 - Previous work by many groups has documented induction of the human immunodeficiency virus (HIV) long terminal repeat (LTR) following exposure of cells to ultraviolet light and other DNA damaging agents. Our experiments set out to determine the relative activation or repression of the HIV-LTR in response to two classes of chemotherapeutic agents: Doxorubicin is a DNA damage-inducing agent, and 5-fluorouracil has an antimetabolic mode of action. Using HeLa cells stably transfected with a construct in which HIV-LTR drives expression of the chloramphenicol acetyl transferase reporter gene, we demonstrated an up to ten-fold induction following doxorubicin treatment at 24 h post-treatment. This induction was repressed by treatment with salicylic acid, suggesting a role for prostaglandin/cyclo-oxygenase pathways and/or NF-κB in the inductive response. Induction by 5-fluorouracil, in contrast, was more modest (two-fold at most) though it was consistently elevated over controls.

AB - Previous work by many groups has documented induction of the human immunodeficiency virus (HIV) long terminal repeat (LTR) following exposure of cells to ultraviolet light and other DNA damaging agents. Our experiments set out to determine the relative activation or repression of the HIV-LTR in response to two classes of chemotherapeutic agents: Doxorubicin is a DNA damage-inducing agent, and 5-fluorouracil has an antimetabolic mode of action. Using HeLa cells stably transfected with a construct in which HIV-LTR drives expression of the chloramphenicol acetyl transferase reporter gene, we demonstrated an up to ten-fold induction following doxorubicin treatment at 24 h post-treatment. This induction was repressed by treatment with salicylic acid, suggesting a role for prostaglandin/cyclo-oxygenase pathways and/or NF-κB in the inductive response. Induction by 5-fluorouracil, in contrast, was more modest (two-fold at most) though it was consistently elevated over controls.

KW - 5-Fluorouracil

KW - Chemotherapeutic agents

KW - Doxorubicin/adriamycin

KW - Human immunodeficiency virus (HIV) gene expression

KW - Long terminal repeat of HIV

UR - http://www.scopus.com/inward/record.url?scp=0030565023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030565023&partnerID=8YFLogxK

U2 - 10.1016/0304-3835(96)04285-1

DO - 10.1016/0304-3835(96)04285-1

M3 - Article

C2 - 8697447

AN - SCOPUS:0030565023

SN - 0304-3835

VL - 105

SP - 217

EP - 223

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this